{"analyses":[{"ciLowerLimit":"1.310","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.160","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":">0.9999","paramType":"Hazard Ratio (HR)","paramValue":"1.68","statisticalComment":"1-sided","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.607","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.011","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0301","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalComment":"1-sided","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"1.9","value":"1.9"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"5.1","value":"3.7"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"4.0","value":"3.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"description":"PFS is defined as the time from date of randomization to the date of the first documentation of progression of disease (PD) or death due to any cause, whichever occurs first. PFS time was summarized by treatment arm using the Kaplan-Meier method. PFS based on BICR assessment was evaluated for this endpoint.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEDIAN","populationDescription":"The primary analyses of PFS based on BICR assessment were performed using FAS. The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From randomization to date of first documentation of PD or death due to any cause whichever was first (up to 30 months); based on cutoff date: 19 September 2018.","title":"Progression Free Survival (PFS) Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","type":"PRIMARY","unitOfMeasure":"months"}